ARK Invest bought $1.1 million worth of the crypto firm's 33,022 shares via two funds yesterday: The asset manager also ...
However, there are certain things AI can't do -- and may never be able to do. One of them is to cure diseases. Biotech ...
In November 2023, the UK became the first country in the world to authorise a Crispr gene-editing therapy.
CRISPR Therapeutics AG (NASDAQ:CRSP) is among the Growth Stock Portfolio: 12 Stock Picks By Cathie Wood. On January 22, 2026, ...
DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...
Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in ...
The hold followed Intellia’s voluntary pause in response to a grade 4 liver event—a case of Hy’s Law—in the ATTR-CM trial.
Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, ...
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $54.65, marking a -1.57% move from the previous day.
One of the most inherent risks is the risk of damaging healthy genes. This rather brutal issue is step one of risk management. It also means large sequences of amino acids that must be checked, ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is a trending stock: Facts to know before betting on it
CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
Earlier this month, Intellia Therapeutics presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results